Ureteral Disease

Categories: Nephrological diseases

Aliases & Classifications for Ureteral Disease

MalaCards integrated aliases for Ureteral Disease:

Name: Ureteral Disease 12 15
Ureteral Diseases 44 73
Ureteral Disorders 43
Disorder of Ureter 73


External Ids:

Disease Ontology 12 DOID:1426
MeSH 44 D014515
NCIt 50 C27148

Summaries for Ureteral Disease

MedlinePlus : 43 Your kidneys make urine by filtering wastes and extra water from your blood. The urine travels from the kidneys to the bladder in two thin tubes called ureters. The ureters are about 8 to 10 inches long. Muscles in the ureter walls tighten and relax to force urine down and away from the kidneys. Small amounts of urine flow from the ureters into the bladder about every 10 to 15 seconds. Sometimes the ureters can become blocked or injured. This can block the flow of urine to the bladder. If urine stands still or backs up the ureter, you may get a urinary tract infections. Doctors diagnose problems with the ureters using different tests. These include urine tests, x-rays, and examination of the ureter with a scope called a cystoscope. Treatment depends on the cause of the problem. It may include medicines and, in severe cases, surgery. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Ureteral Disease, also known as ureteral diseases, is related to vesicoureteral reflux 1 and ureterocele. An important gene associated with Ureteral Disease is SLC3A1 (Solute Carrier Family 3 Member 1), and among its related pathways/superpathways are Development EGFR signaling pathway and Mesodermal Commitment Pathway. The drugs Tamsulosin and Morphine have been mentioned in the context of this disorder. Affiliated tissues include kidney, testes and smooth muscle, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A urinary system disease that is located in the ureter.

Wikipedia : 76 In human anatomy, the ureters are tubes made of smooth muscle fibers that propel urine from the kidneys... more...

Related Diseases for Ureteral Disease

Diseases related to Ureteral Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 27)
# Related Disease Score Top Affiliating Genes
1 vesicoureteral reflux 1 30.7 C16orf58 MCU PAX2 REN ROBO2 SOX17
2 ureterocele 11.0
3 hypertrophic scars 10.2 SMAD2 SMAD3 TGFB1
4 peyronie's disease 10.1 SMAD3 SMAD7 TGFB1
5 hypochondrogenesis 10.1 SMAD2 SMAD3 SMAD7
6 multicystic dysplastic kidney 10.1 PAX2 REN
7 spastic paraplegia 3, autosomal dominant 10.1 CDH1 SMAD2 TGFB1
8 inappropriate adh syndrome 10.1 AQP2 REN
9 clear cell adenocarcinoma 10.1 PAX2 SMAD2 SMAD3
10 obstructive nephropathy 10.1 REN SMAD2 SMAD3 TGFB1
11 keloids 10.1 SMAD2 SMAD3 SMAD7 TGFB1
12 familial vesicoureteral reflux 10.1 ROBO2 SOX17 TGFB1
13 bladder disease 10.0 CDH1 SLC3A1 SLC7A9 UPK3A
14 pauci-immune glomerulonephritis 10.0 CCN2 SMAD2
15 hypotonia-cystinuria syndrome 10.0 PPM1B PREPL SLC3A1 SLC7A9
16 spondylocarpotarsal synostosis syndrome 10.0 CCN2 SMAD2 SMAD3
17 stiff skin syndrome 9.9 CCN2 TGFB1
18 pulmonary fibrosis 9.9 CCN2 SMAD3 SMAD7 TGFB1
19 urinary system disease 9.9 AQP2 CCN2 REN TGFB1
20 autosomal dominant polycystic kidney disease 9.9 AQP2 CDH1 REN
21 nephrogenic systemic fibrosis 9.9 CCN2 SMAD2 SMAD3 SMAD7 TGFB1
22 liver cirrhosis 9.9 AQP2 CCN2 REN TGFB1
23 pulmonary fibrosis, idiopathic 9.8 CCN2 CDH1 SMAD2 SMAD3 TGFB1
24 kidney disease 9.8 AQP2 CCN2 PAX2 REN TGFB1
25 cystinuria 9.7 PREPL SLC3A1 SLC3A2 SLC6A18 SLC7A9
26 renal fibrosis 9.7 CCN2 CDH1 REN SMAD2 SMAD3 SMAD7
27 urinary tract obstruction 9.4 AQP2 C16orf58 CCN2 CDH1 REN SMAD2

Graphical network of the top 20 diseases related to Ureteral Disease:

Diseases related to Ureteral Disease

Symptoms & Phenotypes for Ureteral Disease

MGI Mouse Phenotypes related to Ureteral Disease:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.27 CCN2 CDH1 MCU PAX2 REN ROBO2
2 homeostasis/metabolism MP:0005376 10.27 AQP2 CCN2 CDH1 MCU REN ROBO2
3 cellular MP:0005384 10.22 CCN2 CDH1 MCU PAX2 ROBO2 SLC3A2
4 growth/size/body region MP:0005378 10.22 AQP2 CCN2 CDH1 MCU PREPL REN
5 mortality/aging MP:0010768 10.13 AQP2 CCN2 CDH1 MCU PAX2 PPM1B
6 digestive/alimentary MP:0005381 10.11 CCN2 CDH1 ROBO2 SLC3A2 SMAD2 SMAD3
7 embryo MP:0005380 10.09 CCN2 CDH1 PAX2 PPM1B SMAD2 SMAD3
8 immune system MP:0005387 10.02 CDH1 REN SLC3A1 SLC3A2 SLC7A9 SMAD2
9 muscle MP:0005369 9.76 MCU PREPL REN ROBO2 SLC3A1 SMAD7
10 renal/urinary system MP:0005367 9.65 AQP2 PAX2 REN ROBO2 SLC3A1 SLC6A18
11 reproductive system MP:0005389 9.32 AQP2 CDH1 PAX2 REN ROBO2 SMAD2

Drugs & Therapeutics for Ureteral Disease

Drugs for Ureteral Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 209)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 106133-20-4 129211
Morphine Approved, Investigational Phase 4 57-27-2 5288826
3 Nefopam Approved, Investigational Phase 4 13669-70-0
Ketoprofen Approved, Vet_approved Phase 4 22071-15-4 3825
Silodosin Approved Phase 4,Phase 2 160970-54-7
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
8 Naftopidil Investigational Phase 4,Phase 3 57149-07-2
9 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
10 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
11 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
12 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
13 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
14 Calcium, Dietary Phase 4,Phase 3,Phase 2
15 Antihypertensive Agents Phase 4,Phase 3
16 Platelet Aggregation Inhibitors Phase 4,Phase 3
17 calcium channel blockers Phase 4,Phase 3
18 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
19 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2,Not Applicable
20 Central Nervous System Depressants Phase 4,Phase 2,Not Applicable
21 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
22 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Vasodilator Agents Phase 4,Phase 3
24 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Not Applicable
25 Cyclooxygenase Inhibitors Phase 4,Not Applicable
26 Anti-Inflammatory Agents Phase 4,Phase 3,Not Applicable
27 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Not Applicable
28 Tolterodine tartrate Phase 4 124937-52-6
29 Cholinergic Agents Phase 4,Not Applicable
30 Cholinergic Antagonists Phase 4,Not Applicable
31 Muscarinic Antagonists Phase 4,Not Applicable
32 Narcotics Phase 4,Not Applicable
33 Analgesics, Opioid Phase 4,Not Applicable
34 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
35 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 1,Phase 2
36 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2
37 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
38 Cytochrome P-450 Enzyme Inhibitors Phase 4
39 Cyclooxygenase 2 Inhibitors Phase 4,Not Applicable
40 Sildenafil Citrate Phase 4 171599-83-0
41 Citrate Phase 4
42 Phosphodiesterase 5 Inhibitors Phase 4
43 Phosphodiesterase Inhibitors Phase 4
Doxazosin Approved Phase 3 74191-85-8 3157
Prazosin Approved Phase 3 19216-56-9 4893
Alfuzosin Approved, Investigational Phase 3,Phase 2 81403-80-7 2092
Nifedipine Approved Phase 3 21829-25-4 4485
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750

Interventional clinical trials:

(show top 50) (show all 181)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of a Covered Self-expandable Dual-layered Metallic Mesh Stent (UVENTA) in Ureteral Obstruction Unknown status NCT01788865 Phase 4
2 Treatment of Upper Ureteric Stones Unknown status NCT02469766 Phase 4
3 Efficacy of Tamsulosin Oral-controlled Absorption System (OCAS) in the Treatment of Distal Ureteral Stones Unknown status NCT01167062 Phase 4 Tamsulosin Hydrochloride OCAS 0.4 mg
4 The Use of Medical-Expulsive Therapy With Alfuzocine xl 10mg x1/d for Distal Ureterolithiasis.a Randomized Prospective Study Unknown status NCT00489112 Phase 4 Alfuzocine XL 10 mg once a day
5 Naftopidil 75mg for Improving Clearance of Urinary Stones Unknown status NCT02011737 Phase 4 naftopidil 75mg
6 Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction Completed NCT01741454 Phase 4 Tamsulosin;Tolterodine ER
7 Functional MR Urography Completed NCT00301470 Phase 4
8 Nefopam and Morphine Consumption in the Treatment of Ureteral Calculi Completed NCT00639574 Phase 4 Néfopam
9 Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones Completed NCT01533389 Phase 4 Silodosin;Placebo
10 Tamsulosin for Urolithiasis in the Emergency Dept Completed NCT00382265 Phase 4 tamsulosin
11 Tamsulosin as Adjuvant Treatment Prior to Endoscopic Ureterolithotomy Recruiting NCT03614052 Phase 4 Tamsulosin Hydrochloride 0.4 MG;Placebo Oral Tablet
12 Antibiotic Prophylaxis Before Shock Wave Lithotripsy Recruiting NCT03692715 Phase 4 Ciprofloxacin;Placebo
13 Phosphodiesterase 5 Inhibitors (PDE5i) (Sildenafil) as Medical Expulsive Therapy in Distal Ureteral Stones Active, not recruiting NCT02519153 Phase 4 Sildenafil
14 Daily Versus Twice Per Day Tamsulosin for Ureteral Stent Symptoms Not yet recruiting NCT03799120 Phase 4 Tamsulosin BID
15 Silodosin Versus Tamsulosin for Treatment of Ureteral Stones Terminated NCT02369744 Phase 4 Silodosin;Tamsulosin
16 Celecoxib (Celebrex) in the Management of Acute Renal Colic Withdrawn NCT00304317 Phase 4 celecoxib
17 Alfuzosin for Medical Expulsion Therapy of Ureteral Stones Unknown status NCT00713739 Phase 3 Alfuzosin;nifedipine;doxazosin;prazosin
18 Evaluation of Tamsulosin in the Treatment of Ureteral Stones Completed NCT00151567 Phase 3 Tamsulosin;Placebo
19 Medical Expulsive Therapy for Ureter Stone Using Naftopidil Completed NCT01952314 Phase 3 Naftopidil 75mg;Placebo for Naftopidil;Standard treatment
20 Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi Completed NCT00177086 Phase 3
21 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
22 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
23 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
24 A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) Recruiting NCT03474107 Phase 3 enfortumab vedotin;docetaxel;vinflunine;paclitaxel
25 Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma Recruiting NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
26 Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Recruiting NCT03193788 Phase 3 pemetrexed;Folic Acid;Vitamin B12 Injection;Dexamethasone
27 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
28 Comparison of Silicone-covered Metallic Ureteral Stent and Double-J Stent for Malignant Ureteral Obstruction Unknown status NCT01823575 Phase 2
29 Comparing Patients After ESWL Treated With Ureteral Stents Versus Expulsion Therapy With Tamsulosin Unknown status NCT00478998 Phase 2 Tamsulosin
30 Does Treatment With Alfuzosin Increase Success Rates of (SWL) Shock Wave Lithotripsy Unknown status NCT00409227 Phase 2 Alpha blocker-alfuzosin;placebo
31 A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
32 Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer Unknown status NCT01191892 Phase 2 carboplatin;gemcitabine hydrochloride;vandetanib;Placebo
33 Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer Unknown status NCT01118039 Phase 2 sunitinib malate
34 Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer Unknown status NCT00005958 Phase 2 docetaxel;gemcitabine hydrochloride
35 Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract Unknown status NCT00006111 Phase 2 cisplatin;fluorouracil
36 A Randomized Control Trial Comparing Single vs. Multiple Application of Lidocaine Analgesia Prior to Urethral Catheterization Procedures Completed NCT00142064 Phase 2
37 Tolerance and Effectiveness of Ureteral Stents MEMOKATH ® 051 in Chronic Strictures of the Ureter Completed NCT00790686 Phase 2
38 Study of Silodosin to Facilitate Passage of Urinary Stones Completed NCT01144949 Phase 2 silodosin;placebo
39 Assessment of Drug-eluting Ureteral Stent on Bacterial Adherence and Biofilm Formation Completed NCT00250406 Phase 2
40 TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma Completed NCT01328574 Phase 2 TRC105
41 Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum Completed NCT01426126 Phase 2 Genexol PM
42 Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium Completed NCT01090466 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;temsirolimus
43 Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT) Completed NCT01089088 Phase 2 cisplatin;gemcitabine hydrochloride;sunitinib malate
44 Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment Completed NCT01031875 Phase 2 pazopanib hydrochloride
45 Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer Completed NCT00792025 Phase 2 sunitinib malate
46 A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer Completed NCT00661609 Phase 2 AZD4877
47 Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function Completed NCT00478361 Phase 2 Gemcitabine hydrochloride;Paclitaxel;Doxorubicin hydrochloride;Pegfilgrastim
48 Pazopanib in Treating Patients With Metastatic Urothelial Cancer Completed NCT00471536 Phase 2 pazopanib hydrochloride
49 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Completed NCT00407485 Phase 2
50 Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium Completed NCT00397488 Phase 2 sunitinib malate

Search NIH Clinical Center for Ureteral Disease

Cochrane evidence based reviews: ureteral diseases

Genetic Tests for Ureteral Disease

Anatomical Context for Ureteral Disease

MalaCards organs/tissues related to Ureteral Disease:

Kidney, Testes, Smooth Muscle, Skin, Liver

The Foundational Model of Anatomy Ontology organs/tissues related to Ureteral Disease:

The Ureter

Publications for Ureteral Disease

Articles related to Ureteral Disease:

# Title Authors Year
In vitro, in vivo, and clinical tests of a novel flexible ureteroscope for the diagnosis and treatment of kidney and ureteral diseases. ( 30182078 )
Reno-ureteral diseases inducing hypertension in children. ( 19480305 )
Extensive dilation of distal ureter for endoscopic treatment of large volume ureteral disease. ( 7869503 )
Ureteroscopy with rigid instruments in the management of distal ureteral disease. ( 6737571 )
Ipsilateral ureteroureterostomy for single ureteral disease in patients with ureteral duplication: a review of 8 years of experience with 16 patients. ( 650746 )
Role of the excretory urogram in the diagnosis of renal and ureteral disease. ( 4479909 )
Transureteroureterostomy in the management of distal ureteral disease. ( 5047409 )

Variations for Ureteral Disease

Expression for Ureteral Disease

Search GEO for disease gene expression data for Ureteral Disease.

Pathways for Ureteral Disease

Pathways related to Ureteral Disease according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
3 12.26 CDH1 SMAD2 SMAD3 TGFB1
Show member pathways
5 12.09 CDH1 SMAD2 SMAD3 TGFB1
8 11.99 CCN2 CDH1 SMAD2 SMAD3
Show member pathways
12 11.79 SMAD2 SMAD3 TGFB1
13 11.78 SMAD2 SMAD3 SMAD7 TGFB1
Show member pathways
Show member pathways
17 11.67 SMAD2 SMAD3 SMAD7
18 11.62 CDH1 SMAD2 SMAD3
19 11.62 SMAD2 SMAD3 SMAD7 TGFB1
20 11.56 CCN2 SMAD7 TGFB1
Show member pathways
Show member pathways
23 11.39 SMAD2 SMAD3 SMAD7 TGFB1
24 11.18 SMAD2 SMAD3 TGFB1
25 11.08 CCN2 SMAD2 SMAD3
Show member pathways
11.08 SLC3A1 SLC3A2 SLC6A18 SLC7A9
27 10.91 SMAD2 SMAD3
29 10.51 CDH1 SMAD2 SMAD3 TGFB1

GO Terms for Ureteral Disease

Cellular components related to Ureteral Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor complex GO:0005667 9.62 SMAD2 SMAD3 SMAD7 SOX17
2 apical plasma membrane GO:0016324 9.35 AQP2 SLC3A2 SLC6A18 SLC7A9 UPK3A
3 brush border membrane GO:0031526 9.33 SLC3A1 SLC6A18 SLC7A9
4 SMAD protein complex GO:0071141 9.26 SMAD2 SMAD3
5 heteromeric SMAD protein complex GO:0071144 8.62 SMAD2 SMAD3
6 plasma membrane GO:0005886 10.15 AQP2 CCN2 CDH1 REN ROBO2 SLC3A1

Biological processes related to Ureteral Disease according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 kidney development GO:0001822 9.86 REN ROBO2 UPK3A
2 wound healing GO:0042060 9.85 SMAD2 SMAD3 TGFB1
3 response to organic substance GO:0010033 9.84 CDH1 REN TGFB1
4 response to glucose GO:0009749 9.81 CCN2 SMAD2 TGFB1
5 cellular response to transforming growth factor beta stimulus GO:0071560 9.79 SMAD3 SMAD7 TGFB1
6 transforming growth factor beta receptor signaling pathway GO:0007179 9.78 SMAD2 SMAD3 SMAD7 TGFB1
7 SMAD protein signal transduction GO:0060395 9.77 SMAD2 SMAD3 TGFB1
8 positive regulation of epithelial to mesenchymal transition GO:0010718 9.74 SMAD2 SMAD3 TGFB1
9 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.73 SMAD2 SMAD3 SMAD7 TGFB1
10 gastrulation GO:0007369 9.71 SMAD2 SMAD3 SOX17
11 amino acid transport GO:0006865 9.71 SLC3A1 SLC3A2 SLC6A18 SLC7A9
12 positive regulation of protein import into nucleus GO:0042307 9.7 CDH1 SMAD3 TGFB1
13 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.69 PAX2 TGFB1
14 water transport GO:0006833 9.69 AQP2 UPK3A
15 activin receptor signaling pathway GO:0032924 9.68 SMAD2 SMAD3
16 L-alpha-amino acid transmembrane transport GO:1902475 9.68 SLC3A1 SLC7A9
17 negative regulation of cell-cell adhesion GO:0022408 9.68 CDH1 TGFB1
18 neutral amino acid transport GO:0015804 9.67 SLC6A18 SLC7A9
19 lens fiber cell differentiation GO:0070306 9.66 SMAD3 TGFB1
20 mesonephros development GO:0001823 9.66 PAX2 REN
21 pathway-restricted SMAD protein phosphorylation GO:0060389 9.65 SMAD7 TGFB1
22 endoderm formation GO:0001706 9.65 SMAD2 SOX17
23 nodal signaling pathway GO:0038092 9.65 SMAD2 SMAD3
24 primary miRNA processing GO:0031053 9.64 SMAD2 SMAD3
25 response to cholesterol GO:0070723 9.64 SMAD2 TGFB1
26 pericardium development GO:0060039 9.63 SMAD2 SMAD3
27 signal transduction involved in regulation of gene expression GO:0023019 9.63 SMAD2 SMAD3 SOX17
28 response to laminar fluid shear stress GO:0034616 9.62 SMAD7 TGFB1
29 metanephric collecting duct development GO:0072205 9.61 AQP2 PAX2
30 common-partner SMAD protein phosphorylation GO:0007182 9.59 SMAD2 TGFB1
31 positive regulation of extracellular matrix assembly GO:1901203 9.58 SMAD3 TGFB1
32 L-cystine transport GO:0015811 9.56 SLC3A1 SLC7A9
33 endoderm development GO:0007492 9.56 SMAD2 SMAD3 SOX17 TGFB1
34 regulation of striated muscle tissue development GO:0016202 9.55 SMAD3 TGFB1
35 embryonic foregut morphogenesis GO:0048617 9.54 SMAD2 SMAD3 SOX17
36 evasion or tolerance of host defenses by virus GO:0019049 9.51 SMAD3 TGFB1
37 SMAD protein complex assembly GO:0007183 9.5 SMAD2 SMAD3 TGFB1
38 paraxial mesoderm morphogenesis GO:0048340 9.49 SMAD2 SMAD3
39 regulation of binding GO:0051098 9.33 SMAD2 SMAD3 TGFB1
40 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.26 SMAD2 SMAD3 SMAD7 TGFB1
41 ureteric bud development GO:0001657 9.02 ROBO2 SMAD2 SMAD3 SMAD7 TGFB1
42 positive regulation of transcription, DNA-templated GO:0045893 10.05 CDH1 PAX2 SMAD2 SMAD3 SOX17 TGFB1
43 positive regulation of gene expression GO:0010628 10.02 CCN2 SMAD2 SMAD3 SOX17 TGFB1

Molecular functions related to Ureteral Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.92 SLC3A1 SMAD2 SMAD3 SOX17 TGFB1
2 transcription regulatory region DNA binding GO:0044212 9.78 PAX2 SMAD3 SMAD7 SOX17
3 amino acid transmembrane transporter activity GO:0015171 9.58 SLC3A1 SLC6A18 SLC7A9
4 enhancer binding GO:0035326 9.54 SMAD2 SMAD3
5 transforming growth factor beta receptor binding GO:0005160 9.54 SMAD2 SMAD3 TGFB1
6 co-SMAD binding GO:0070410 9.51 SMAD2 SMAD3
7 I-SMAD binding GO:0070411 9.49 SMAD2 SMAD7
8 primary miRNA binding GO:0070878 9.46 SMAD2 SMAD3
9 beta-catenin binding GO:0008013 9.46 CDH1 SMAD3 SMAD7 SOX17
10 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 9.43 SMAD2 SMAD3
11 L-cystine transmembrane transporter activity GO:0015184 9.32 SLC3A1 SLC7A9
12 neutral amino acid transmembrane transporter activity GO:0015175 9.13 SLC3A2 SLC6A18 SLC7A9
13 type I transforming growth factor beta receptor binding GO:0034713 8.8 SMAD2 SMAD7 TGFB1
14 protein binding GO:0005515 10.21 AQP2 CCN2 CDH1 MCU PAX2 PPM1B

Sources for Ureteral Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
70 SNOMED-CT via Orphanet
72 Tocris
74 UMLS via Orphanet
Loading form....